ChemoCentryx Reports Third Quarter 2021 Financial Results and Recent Highlights
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St set to gain on tech rebound, Middle East in focus
- Oracle results beat estimates, but shares fall on plans for $40 billion raise
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Alibaba falls on China AI capex report; Citi says selloff is premature
- Crude Inventory Fell 7.2 Million Barrels Last Week, Says EIA
ChemoCentryx (CCXI) Tops Q3 EPS by 13c
November 9, 2021 5:09 PM ESTChemoCentryx (NASDAQ: CCXI) reported Q3 EPS of ($0.32), $0.13 better than the analyst estimate of ($0.45). Revenue for the quarter came in at $17.7 million versus the consensus estimate of $13.48 million.
For earnings history and earnings-related data on ChemoCentryx (CCXI) click here.
... More